PMID- 38439837
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240306
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 10
IP  - 5
DP  - 2024 Mar 15
TI  - Bridging the gap between statistical significance and clinical relevance: A 
      systematic review of minimum clinically important difference (MCID) thresholds of 
      scales reported in movement disorders research.
PG  - e26479
LID - 10.1016/j.heliyon.2024.e26479 [doi]
LID - e26479
AB  - BACKGROUND: Minimum clinically important difference (MCID) is the smallest change 
      in an outcome measure that is considered clinically meaningful. Using validated 
      MCID thresholds for outcomes powers trials adequately to detect meaningful 
      treatment effects, aids in their interpretation and guides development of new 
      outcome measures. OBJECTIVES: To provide a comprehensive summary of MCID 
      thresholds of various symptom severity scales reported in movement disorder. 
      METHODS: We conducted systematic review of the literature and included studies of 
      one or more movement disorders, and reporting MCID scales. RESULTS: 2763 reports 
      were screened. Final review included 32 studies. Risk of bias (RoB) assessment 
      showed most studies were of good quality. Most commonly evaluated scale was 
      Unified Parkinson's Disease Rating Scale (UPDRS) (11 out of 32). Four studies 
      assessing MDS-UPDRS had assessed its different sub-parts, reporting a change of 
      2.64,3.05,3.25 and 0.9 points to detect clinically meaningful improvement and 
      2.45,2.51,4.63 and 0.8 points to detect clinically meaningful worsening, for the 
      Part I, II, III and IV, respectively. For Parts II + III, I + II + III and 
      I + II + III + IV, MCID thresholds reported for clinically meaningful improvement 
      were 5.73, 4.9, 6.7 and 7.1 points respectively; while those for clinically 
      meaningful worsening were 4.7, 4.2, 5.2 and 6.3 points, respectively. MCID 
      thresholds reported for other scales included Abnormal Involuntary Movement Scale 
      (AIMS), Toronto Western Spasmodic Torticollis Rating Scale (TWSRS), and 
      Burke-Fahn-Marsden Dystonia Scale (BFMD). CONCLUSION: This review summarizes all 
      the MCID thresholds currently reported in Movement disorders research and 
      provides a comprehensive resource for future trials, highlighting the need for 
      standardized and validated MCID scales in movement disorder research.
CI  - (c) 2024 The Authors.
FAU - Mishra, Biswamohan
AU  - Mishra B
AD  - Department of Neurology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Sudheer, Pachipala
AU  - Sudheer P
AD  - Department of Neurology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Rajan, Roopa
AU  - Rajan R
AD  - Department of Neurology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Agarwal, Ayush
AU  - Agarwal A
AD  - Department of Neurology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Srivastava, M V Padma
AU  - Srivastava MVP
AD  - Department of Neurology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Nilima, Nilima
AU  - Nilima N
AD  - Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Vishnu, Venugopalan Y
AU  - Vishnu VY
AD  - Department of Neurology, All India Institute of Medical Sciences, New Delhi, 
      India.
LA  - eng
PT  - Journal Article
DEP - 20240220
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC10909673
OTO - NOTNLM
OT  - Ataxia
OT  - Clinical relevance
OT  - Dystonia
OT  - MCID
OT  - Minimal clinical important difference
OT  - Minimal clinically important change
OT  - Movement disorders
OT  - Parkinsonism
OT  - Patient-reported outcome measures (PROMs)
OT  - Tardive dyskinesia
OT  - Tremor
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2024/03/05 06:43
MHDA- 2024/03/05 06:44
PMCR- 2024/02/20
CRDT- 2024/03/05 03:45
PHST- 2023/11/08 00:00 [received]
PHST- 2024/01/16 00:00 [revised]
PHST- 2024/02/14 00:00 [accepted]
PHST- 2024/03/05 06:44 [medline]
PHST- 2024/03/05 06:43 [pubmed]
PHST- 2024/03/05 03:45 [entrez]
PHST- 2024/02/20 00:00 [pmc-release]
AID - S2405-8440(24)02510-6 [pii]
AID - e26479 [pii]
AID - 10.1016/j.heliyon.2024.e26479 [doi]
PST - epublish
SO  - Heliyon. 2024 Feb 20;10(5):e26479. doi: 10.1016/j.heliyon.2024.e26479. 
      eCollection 2024 Mar 15.